Literature DB >> 22071714

Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease.

Bram van den Borst1, Harry R Gosker, Geertjan Wesseling, Wilco de Jager, Valéry A C V Hellwig, Frank J Snepvangers, Annemie M W J Schols.   

Abstract

BACKGROUND: Low-grade systemic inflammation is common in chronic obstructive pulmonary disease (COPD), but its source remains unclear. Adipose tissue is a potent producer of inflammatory mediators and may contribute to systemic inflammation in COPD, possibly via hypoxia.
OBJECTIVE: We studied the influence of COPD and exercise-induced oxygen desaturation on adipose tissue inflammation (ATI) and its contribution to systemic inflammation.
DESIGN: Subcutaneous adipose tissue biopsies were investigated in 28 clinically stable COPD patients [forced expiratory volume in 1 s: 58 ± 16% predicted; BMI (in kg/m(2)): 24.9 ± 2.9] and 15 age-, sex-, and body composition-matched healthy control subjects. Fat mass was measured with dual-energy X-ray absorptiometry. Patients were prestratified by oxygen desaturation assessed by incremental cycle ergometry. The adipocyte size and adipose tissue expression of 19 inflammatory and hypoxia-related genes were measured, and adipose tissue macrophages (ATMs) were histologically quantified. Systemic inflammatory markers included C-reactive protein (CRP) and a panel of 20 adipokines.
RESULTS: COPD patients had comparable fat mass but higher CRP and HOMA-IR than did control subjects. COPD patients and control subjects had comparable adipose tissue gene expression, adipocyte size, ATM infiltration, and systemic adipokine concentrations. Desaturating COPD patients had no different ATI status than did nondesaturating COPD patients. COPD patients with high CRP had significantly greater ATM infiltration than did patients with low CRP, which was independent of BMI and fat mass.
CONCLUSIONS: In COPD patients, mild-to-moderate COPD, per se, does not enhance ATI or its contribution to systemic inflammation compared with in well-matched healthy control subjects. However, to our knowledge, our study provides a first indication for a possible role of ATMs in the systemic inflammatory response in COPD that requires additional investigation. This trial was registered at www.trialregister.nl as NTR1402.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071714     DOI: 10.3945/ajcn.111.023911

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  15 in total

1.  The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease.

Authors:  Bram van den Borst; Harry R Gosker; Annemarie Koster; Binbing Yu; Stephen B Kritchevsky; Yongmei Liu; Bernd Meibohm; Thomas B Rice; Michael Shlipak; Sachin Yende; Tamara B Harris; Annemie M W J Schols
Journal:  Am J Clin Nutr       Date:  2012-07-18       Impact factor: 7.045

2.  Effect of CSE on M1/M2 polarization in alveolar and peritoneal macrophages at different concentrations and exposure in vitro.

Authors:  Haoshen Feng; Yan Yin; Yuan Ren; Menglu Li; Dan Zhang; Mingtao Xu; Xu Cai; Jian Kang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2020-01-02       Impact factor: 2.416

Review 3.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 4.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

Review 5.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

Review 6.  Body weight and mortality in COPD: focus on the obesity paradox.

Authors:  Francesco Spelta; A M Fratta Pasini; L Cazzoletti; M Ferrari
Journal:  Eat Weight Disord       Date:  2017-11-06       Impact factor: 4.652

7.  Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers.

Authors:  Alejandro A Diaz; Linfu Zhou; Tom P Young; Merry-Lynn McDonald; Rola Harmouche; James C Ross; Raul San Jose Estepar; Emiel F M Wouters; Harvey O Coxson; William MacNee; Stephen Rennard; François Maltais; Gregory L Kinney; John E Hokanson; George R Washko
Journal:  Acad Radiol       Date:  2014-08-01       Impact factor: 3.173

8.  Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD.

Authors:  Jun Kojima; Jun Araya; Hiromichi Hara; Saburo Ito; Naoki Takasaka; Kenji Kobayashi; Satoko Fujii; Chikako Tsurushige; Takanori Numata; Takeo Ishikawa; Kenichiro Shimizu; Makoto Kawaishi; Keisuke Saito; Noriki Kamiya; Jun Hirano; Makoto Odaka; Toshiaki Morikawa; Hiroshi Hano; Satoko Arai; Toru Miyazaki; Yumi Kaneko; Katsutoshi Nakayama; Kazuyoshi Kuwano
Journal:  Respir Res       Date:  2013-03-05

9.  Low Serum retinol-binding protein-4 levels in acute exacerbations of chronic obstructive pulmonary disease at intensive care unit admission is a predictor of mortality in elderly patients.

Authors:  Qihui Jin; Yueliang Chen; Yufeng Lou; Xiaojun He
Journal:  J Inflamm (Lond)       Date:  2013-10-07       Impact factor: 4.981

Review 10.  Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat.

Authors:  Dukhabandhu Naik; Anjali Joshi; Thomas Vizhalil Paul; Nihal Thomas
Journal:  Indian J Endocrinol Metab       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.